Skip to main content
Livermore
Livermore
ZHEN

AN2 Therapeutics, Inc.

ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001880438

In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.

Holders of 5% or more of ANTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of AN2 Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ANTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Commodore Capital LP13G9.90%3.70M sharesNewMar 16, 20261 filingMar 16, 2026SEC
Coastlands Capital Partners LP13G9.30%2.82M sharesNewJun 4, 20251 filingJun 4, 2025SEC
Vivo Opportunity Fund Holdings, L.P.13G8.00%2.86M sharesNewMar 13, 20261 filingMar 13, 2026SEC
Adjuvant Global Health Technology Fund, L.P.13G/A7.90%2.37M shares–Feb 28, 20251 filingFeb 28, 2025SEC
Easom Eric13G/A7.90%2.23M shares+1.70 ppfrom 6.20%Feb 13, 20252 filingsFeb 13, 2026SEC
Integrated Core Strategies (US) LLC13G6.30%2.24M sharesNewMar 13, 20261 filingMar 13, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

18 Schedule 13D and 13G filings on AN2 Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ANTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 15, 20269:58 PM ETAlmitas Capital LLC13G/A4.10%1.48M shares−1.30 ppfrom 5.40%Below 5%Mar 31, 2026SEC
Mar 16, 20264:21 PM ETCommodore Capital LPand 3 others13G9.90%3.70M sharesNewMar 9, 2026SEC
Mar 13, 20265:02 PM ETIntegrated Core Strategies (US) LLCand 3 others13G6.30%2.24M sharesNewMar 6, 2026SEC
Mar 13, 20264:02 PM ETVivo Opportunity Fund Holdings, L.P.and 3 others13G8.00%2.86M sharesNewMar 10, 2026SEC
Feb 17, 20266:54 PM ETAlmitas Capital LLC13G5.40%2.98M shares+0.20 ppfrom 5.20%Dec 31, 2025SEC
Feb 13, 20264:30 PM ETEasom Eric13G/A7.90%2.23M shares+1.70 ppfrom 6.20%Dec 31, 2025SEC
Nov 14, 20257:51 PM ETAlmitas Capital LLC13G5.20%1.43M sharesNewSep 30, 2025SEC
Jun 18, 202511:08 AM ETBML Investment Partners, L.P.13D/A1.40%427.4K shares−9.30 ppfrom 10.70%Below 5%Jun 17, 2025SEC
Jun 4, 20255:44 PM ETCoastlands Capital Partners LPand 4 others13G9.30%2.82M sharesNewMay 28, 2025SEC
May 30, 20255:46 PM ETBML Investment Partners, L.P.13D/A10.70%3.22M shares−8.40 ppfrom 19.10%May 28, 2025SEC
May 7, 202510:27 AM ETBML Investment Partners, L.P.13D19.10%5.75M shares−0.10 ppfrom 19.20%May 7, 2025SEC
Feb 28, 20257:57 PM ETAdjuvant Global Health Technology Fund, L.P.and 3 others13G/A7.90%2.37M shares–Dec 31, 2024SEC
Feb 14, 20256:27 PM ETRa Capital Management, L.P.and 3 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 14, 20254:44 PM ETTCG Crossover GP I, LLCand 2 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 14, 20254:30 PM ETBrii Biosciences Ltd13G/A3.10%927.2K shares–Below 5%Dec 31, 2024SEC
Feb 14, 202511:07 AM ETFrazier Life Sciences Public Fund, L.P.and 13 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 13, 20254:30 PM ETEasom Eric13G/A6.20%1.89M shares–Dec 31, 2024SEC
Feb 13, 20254:28 PM ETBML Investment Partners, L.P.13G/A19.20%5.75M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell AN2 Therapeutics, Inc. shares.

No Form 144 notices for AN2 Therapeutics, Inc. are on file.